26
|
Lee S, Choi S, Min C, Ji Y, Jung H, Kim M, Yoo H, Kim C, Yi C, kim K. SU-E-J-106: Study of Variation of Internal Taget Volume Between 4DCT and Slow-CT in Respiratory Patterns Using Respiratory Motion Phantom. Med Phys 2014. [DOI: 10.1118/1.4888158] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
27
|
Yi C, He C. DNA Repair by Reversal of DNA Damage. Cold Spring Harb Perspect Biol 2014. [DOI: 10.1101/cshperspect.a023440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Zhou X, Zhang CZ, Lu SX, Chen GG, Li LZ, Liu LL, Yi C, Fu J, Hu W, Wen JM, Yun JP. miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma. Oncogene 2014; 34:965-77. [PMID: 24632613 DOI: 10.1038/onc.2014.35] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2013] [Revised: 12/29/2013] [Accepted: 01/01/2014] [Indexed: 02/07/2023]
Abstract
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies and the third leading cause of cancer-related deaths worldwide. Tumour metastasis is one of the major causes of high mortality. microRNAshave been implicated in HCC metastasis. In this study, we found that miR-625 was frequently downregulated in HCC samples. A decrease in miR-625 was significantly correlated with lymph node anddistance metastasis (P=0.013), the presence of portal venous invasion (P=0.036), tumor-node-metastasis (TNM) stage (P=0.027) and unfavourable overall survival (P=0.003). Compared with primary tumours, miR-625 expression was markedly reduced in portal venous metastatic tumours. Re-expression of miR-625 in HCC cells was remarkably effective in suppressing cell migration andinvasiveness in vitro and in vivo. Mechanistically, miR-625 was confirmed to downregulate IGF2 mRNA-binding protein 1(IGF2BP1) directly, the expression of which was inversely correlated with the level of miR-625 in HCC cell lines and tissues. High expression of IGF2BP1 was frequently found in HCC samples, and associated with poor prognosis. Knockdown of endogenous IGF2BP1 by siRNA exhibited similar effects as the overexpression of miR-625, whereas overexpression of IGF2BP1 (without the 3'-UTR) abrogated miR-625-mediated metastasis inhibition. Interference of the PTEN/HSP27 pathway contributed to miR-625-mediated metastasis inhibition. Taken together, our data suggest that miR-625 might function as an antimetastatic miRNA to have an important role in HCC progression by modulating the IGF2BP1/PTEN pathway. The newly identified miR-625/IGF2BP1 axis represents a new potential therapeutic target for HCC treatment.
Collapse
|
29
|
Lee S, Choi S, Min C, Park S, Jung H, Yi C, Yoo H, Kim M, Ji Y, Kim K. EP-1704: Evaluation of internal target volumes between 4D CT, Slow CT and CBCT according to breath patterns. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31822-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
30
|
Jiao XM, Zhang XG, Xu XUP, Yi C, Bin C, Cheng QP, Gong QQ, Lv XF. Blood glucose fluctuation aggravates lower extremity vascular disease in type 2 diabetes. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2014; 18:2025-2030. [PMID: 25027342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
OBJECTIVES Lower-extremity vascular diseases are important complication of diabetes. In the present study, we investigated the influence of blood glucose fluctuation in type 2 diabetes-associated lower-extremity vascular diseases, and explore the possible mechanism. PATIENTS AND METHODS Patients with type 2 diabetes was assigned to Group B (without lower-extremity vascular disease) and group C (with lower-extremity vascular disease). Healthy subjects (Group A) served as normal controls. All patients received dynamic blood glucose monitoring for 72 h. The mean amplitude of glycemic excursion (MAGE) and the largest amplitude of glycemic excursion (LAGE) were estimated. The levels of von Willebrand factor (vWF), ischemia-modified albumin (IMA), glycosylated hemoglobin (HbA1c), and biochemical indices were examined, and the lower-extremity vascular diseases were scored in patients from group C. RESULTS Groups B and C have higher systolic blood pressure (SBP), total cholesterol (TC) level, high-density lipoprotein cholesterol (HDL-C) level, HbA1c level, and vWF level and lower IMA level than those in Group A (p < 0.05). Elevated MAGE and LAGE were observed in groups B and C as compared with Group A. Correlation analysis revealed that the score of lower-extremity vascular diseases was associated with MAGE, LAGE, SBP, LDL-C, vWF, HbA1c, and IMA (p < 0.05). Stepwise multiple-linear regression analysis revealed that lower-extremity vascular diseases were involved with MAGE, IMA, and vWF. CONCLUSIONS Enhanced fluctuation in patients with type 2 diabetes may promote the occurrence and development of lower-extremity vascular diseases through aggravating vascular endothelial injury.
Collapse
|
31
|
Han S, Choi S, Park S, Jung H, Yi C, Yoo H, Kim M, Kim C, Ji Y, Kim K. EP-1451: Feasibility study of optical stimulated dosimeters for high dose evaluation in SBRT. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31569-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
32
|
Han S, Kim K, Park S, Jung H, Lee S, Kim H, Yi C, Kim M, Ji Y. SU-E-T-38: The Evaluation of High Dose and Dosimetric Characteristics of Optical Stimulated Luminance Dosimeters in the 60CO Unit. Med Phys 2013. [DOI: 10.1118/1.4814473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
33
|
Han S, Kim K, Park S, Lee S, Yi C, Kim H, Jung H, Kim M, Ji Y. SU-E-T-31: The Evaluation of Dosimetric Characteristics of OSLDs Based On Output Correction Factor in Low Energy. Med Phys 2013. [DOI: 10.1118/1.4814465] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
34
|
Lee S, Kim H, Han S, Kim M, Yoo H, Yi C, Park S, Jung H, Ji Y, Kim K. SU-E-T-711: Normal Tissue Tolerance Evaluation Tool for Clinical Protocols. Med Phys 2013. [DOI: 10.1118/1.4815138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
35
|
Di W, Shi X, Zhu Y, Tao Y, Qi W, Luo N, Xiao Z, Yi C, Miao J, Zhang A, Zhang X, Fang Y. Overuse of paracetamol caffeine aspirin powders affects cerebral glucose metabolism in chronic migraine patients. Eur J Neurol 2012; 20:655-62. [PMID: 23114018 DOI: 10.1111/ene.12018] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2012] [Accepted: 09/18/2012] [Indexed: 01/22/2023]
|
36
|
Robinson J, Kingman S, Lester E, Yi C. Microwave remediation of hydrocarbon-contaminated soils – Scale-up using batch reactors. Sep Purif Technol 2012. [DOI: 10.1016/j.seppur.2012.05.020] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
37
|
Yi C, Wang X, Shi X, Zhang X, Chen Z. 18F-FDG PET/CT imaging of multiple myxofibrosarcoma in left upper abdomen and chest wall. Nuklearmedizin 2012. [DOI: 10.3413/pdf-5236-19157] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
38
|
Yi C, Wang X, Shi X, Zhang X, Chen Z. 18F-FDG PET/CT imaging of multiple myxofibrosarcoma in left upper abdomen and chest wall. Nuklearmedizin 2012; 51:N53-N54. [PMID: 23250511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2012] [Accepted: 06/23/2012] [Indexed: 06/01/2023]
|
39
|
Zhu H, Li Z, Mao S, Ma B, Zhou S, Deng L, Liu T, Cui D, Zhao Y, He J, Yi C, Huang Y. Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice. Cancer Gene Ther 2011; 18:884-96. [PMID: 21921942 PMCID: PMC3215997 DOI: 10.1038/cgt.2011.57] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Soluble fms-like tyrosine kinase receptor (sFlt-1) is a soluble form of extramembrane part of vascular endothelial growth factor receptor-1 (VEGFR-1) that has antitumor effects. Bifidobacterium Infantis is a kind of non-pathogenic and anaerobic bacteria that may have specific targeting property of hypoxic environment inside of solid tumors. The aim of this study was to construct Bifidobacterium Infantis-mediated sFlt-1 gene transferring system and investigate its antitumor effect on Lewis lung cancer (LLC) in mice. Our results demonstrated that the Bifidobacterium Infantis-mediated sFlt-1 gene transferring system was constructed successfully and the system could express sFlt-1 at the levels of gene and protein. This system could not only significantly inhibit growth of human umbilical vein endothelial cells induced by VEGF in vitro, but also inhibit the tumor growth and prolong survival time of LLC C57BL/6 mice safely. These data suggest that Bifidobacterium Infantis-mediated sFlt-1 gene transferring system presents a promising therapeutic approach for the treatment of cancer.
Collapse
|
40
|
Krüger T, Ghisari M, Yi C, Bonefeld-Jørgensen E. Levels and effect of serum pops on steroid hormone receptor function in Greenlandic Inuit. Toxicol Lett 2011. [DOI: 10.1016/j.toxlet.2011.05.1002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
41
|
Bi F, Li Q, Zhou C, Yu J, Cai X, Qiu M, Liu J, Yi C, Luo D, Xu F. Preliminary results of a randomized phase II study: Treatment of Chinese patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or the reverse sequence. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4064] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Horikawa Y, Tsuchiya N, Yuasa K, Narita S, Saito M, Takayama K, Nara T, Tsuruta H, Obara T, Numakura K, Satoh S, Habuchi T, Hu X, Guo J, Lin Z, Sun L, Xu Z, Cang C, Wang G, Kanda T, Sakamoto K, Matsuki A, Ohashi R, Hirota S, Fujimori Y, Matsuda Y, Yajima K, Kosugi S, Hatakeyama K, Kitahara K, Watanabe M, Nakazono S, Wada N, Kakizaki H, Li J, Gong FJ, Sun PN, Shen L, Li Q, Li N, Qiu M, Liu J, Yi C, Luo D, Li Z, Gou H, Yang Y, Cao D, Shen Y, Wang X, Xu F, Bi F, Li Q, Zhang X, Li N, Wei W, Luo HY, Wang ZQ, Wang FH, Qiu MZ, Teng KY, Ruan DY, He YJ, Li YH, Xu RH, Matsusaka S, Mizunuma N, Suenaga M, Shinozaki E, Mishima Y, Terui Y, Hatake K, Nara E, Kodaira M, Mishima Y, Yokoyama M, Saotome T, Terui Y, Takahashi S, Hatake K, Nishimura N, Nakano K, Kodaira M, Ueda K, Yamada S, Mishima Y, Yokoyama M, Saotome T, Takahashi S, Terui Y, Hatake K, Nozawa M, Mochida Y, Nishigaki K, Nagae S, Uemura H, Oh SY, Jeong CY, Hong SC, Lee WS, Kim HG, Lee GW, Hwang IG, Jang JS, Kwon HC, Kang JH, Ozaka M, Ogura M, Matsusaka S, Shinozaki E, Suenaga M, Chin K, Mizunuma N, Hatake K, Pua PF, Ganzon D, Chan V, Sailaja K, Vishnupriya S, Raghunadharao D, Markandeya G, Reddy PRK, Reddanna P, Praveen D, Sakamoto K, Kanda T, Matsuki A, Takano T, Hanyu T, Yajima K, Kosugi S, Hirota S, Hatakeyama K, Shigekawa T, Ijichi N, Takayama S, Tsuda H, Ikeda K, Horie K, Osaki A, Saeki T, Inoue S, Subhashini J, Rajesh B, Rajesh I, Ravindran P, Takagi K, Chin K, Oba M, Kuboki Y, Ichimura T, Oto M, Kawazoe Y, Watanabe T, Ozaka M, Ogura M, Suenaga M, Shinozaki E, Matsusaka S, Mizunuma N, Hatake K, Ueda K, Saotome T, Yamada S, Nishimura N, Nara E, Nakano K, Kodaira M, Katsube A, Mishima Y, Terui Y, Yokoyama M, Takahashi S, Hatake K, Yao X, Yang Q, Li C, Diao L, Chen X, Yu Z, Zuo W, Wang Y, He Y, Zhang X, Cai S, Wang Z, Xu J, Zhan W, Zhang YF, Misumi M, Takeuchi H, Nakamiya N, Shigekawa T, Matsuura K, Fujiuchi N, Osaki A, Saeki T. CLINICAL OUTCOMES. Jpn J Clin Oncol 2011. [DOI: 10.1093/jjco/hyq254] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Qiu M, Bi F, Liu J, Li Q, Yi C. Gemcitabine and capecitabine as third-line treatment in patients with metastatic colorectal cancer after failure of irinotecan and oxaliplatin. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.620] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
620 Background: There is no standard chemotherapeutic regimen for patients with advanced colorectal cancer (CRC) progressing after combination regimens including irinotecan and oxaliplatin and having good performance status. 5-FU and gemcitabine are synergistic in preclinical studies of colon cancer cells. And gemcitabine also increases intracellular release of 5-FU from capecitabine. The aim of this study is to evaluate the efficacy and tolerance of the gemcitabine/capecitabine combination as third-line treatment for patients with advanced colorectal cancer. Methods: Between May 2007 and September 2009, the data on 12 patients with metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens reviewed retrospectively. The median patient age was 54.0 years (range 37-77). The ECOG performance status was 0, 1 or 2. All patients has 2 or more previous chemotherapy. Patients received GemCap regimen (oral capecitabine 1,000 mg/m2 twice daily on days 1 to 14 plus Gem 1,000 mg/m2 on days 1 and 8 every 3 weeks). Eleven patients were evaluable for the response and all patients were evaluable for toxicity. Results: No partial response was achieved and disease stabilization in 4 (36.4.3%) cases. Median progression-free survival and median overall survival were 9.1 weeks (range 3.0-18.0) and 22.3 weeks (range 10.5- 53.0). Four patients with disease stabilization had longer median progression-free survival than those with disease progression (13 weeks vs. 6.2 weeks). No toxic deaths occurred. Grade 3 toxicities were thrombocytopenia (in 2 patients), neutropenia (in 2 patients) and mucositis (in 1 patient), hand-foot syndrome (in 1 patient) and GI toxicity (in 2 patients). Conclusions: The combination of gemcitabine and capecitabine was found to be a safe palliative regimen for heavily pretreated patients with metastatic CRC. Despite no patients had radiologic response, patients with disease stabilization achieved better progression-free survival. This regimen seems to be potentially effective regimen in the treatment of CRC. No significant financial relationships to disclose.
Collapse
|
44
|
Chen W, Yan W, Wu S, Xu Z, Yeung KWK, Yi C. Preparation and Properties of Novel Triphenylpyridine-Containing Hyperbranched Polyimides Derived from 2,4,6-Tris(4-aminophenyl)pyridine under Microwave Irradiation. MACROMOL CHEM PHYS 2010. [DOI: 10.1002/macp.201000193] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
45
|
Lee H, Lee K, Ahn M, Hwang H, Lee J, Park K, Kim T, Yi C, Chung M. Proposal of new CT response criteria in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Bi F, Li Q, Zhou C, Yu J, Cai X, Qiu M, Liu J, Yi C, Luo D, Xu F. Treatment of Chinese patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or the reverse sequence. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Cui DD, Huang Y, Mao SH, Chen SC, Qiu M, Ji LL, Yi C. Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7. Braz J Med Biol Res 2010; 42:854-62. [PMID: 19738990 DOI: 10.1590/s0100-879x2009000900013] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2009] [Accepted: 06/18/2009] [Indexed: 02/05/2023] Open
Abstract
The aim of the present study was to determine the effect of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and adriamycin (ADM) on the human breast cancer cell line MCF-7 and to identify potential mechanisms of apoptosis. Cell viability was analyzed by the MTT assay and the synergistic effect was assessed by the Webb coefficient. Apoptosis was quantified using the annexin V-FITC and propidium iodide staining flow cytometry. The mRNA expression of TRAIL receptors was measured by RT-PCR. Changes in the quantities of Bax and caspase-9 proteins were determined by Western blot. MCF-7 cells were relatively resistant to TRAIL (IC50 >10 microg/mL), while MCF-7 cells were sensitive to ADM (IC50 <10 microg/mL). A subtoxic concentration of ADM (0.5 microg/mL) combined with 0.1, 1, or 10 microg/mL TRAIL had a synergistic cytotoxic effect on MCF-7 cells, which was more marked with the combination of TRAIL (0.1 microg/mL) and ADM (0.5 microg/mL). In addition, the combined treatment with TRAIL and ADM significantly increased cell apoptosis from 9.8% (TRAIL) or 17% (ADM) to 38.7%, resulting in a synergistic apoptotic effect, which is proposed to be mediated by up-regulation of DR4 and DR5 mRNA expression and increased expression of Bax and caspase-9 proteins. These results suggest that the combination of TRAIL and ADM might be a promising therapy for breast cancer.
Collapse
|
48
|
Lee J, Tseng CC, Huang WH, Che PC, Tsai YS, Shih HC, Yi C. Wire-reinforced endotracheal tube penetrated by the Harmonic Scalpel. Anaesth Intensive Care 2010; 38:400-401. [PMID: 20369786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
|
49
|
Yi C, Cao Y, Mao SH, Liu H, Ji LL, Xu SY, Zhang M, Huang Y. Recombinant human growth hormone improves survival and protects against acute lung injury in murine Staphylococcus aureus sepsis. Inflamm Res 2009; 58:855-62. [PMID: 19536455 DOI: 10.1007/s00011-009-0056-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2008] [Revised: 05/11/2009] [Accepted: 05/26/2009] [Indexed: 12/20/2022] Open
Abstract
OBJECTIVE To investigate whether recombinant human growth hormone (rhGH) reduces mortality and protects against Staphylococcus aureus sepsis-induced acute lung injury. METHODS The bacteria-positive rate of blood smears and bacteria colony counts in bacteria plate culture, TNFalpha and IL-10 plasma levels, lung injury score, expression of intercellular adhesion molecule-1 (ICAM-1) as well as activation of nuclear factor-kappa B (NF-kappaB) in the lungs were determined 6, 12 and 24 h after 140 KM mice were injected with physiologic saline (i.p. group C, n = 20); S. aureus E311122 (1.75 x 10(12) cfu/L, 40 ml/kg, i.p. group S, n = 60); or S. aureus (as group S) with a subsequent treatment of rhGH (1.0 U kg(-1) day(-1)), i.m. group T, n = 60). The cumulative survival rate of an additional 15 mice from each group was followed for 7 days post S. aureus injection. RESULTS rhGH treatment significantly increased IL-10 plasma levels and the 7-day cumulative survival rate, whereas the bacteria-positive rate of blood smears, bacteria colony counts in bacteria plate cultures, lung injury score, ICAM-1 and NF-kappaB expression in the lungs were significantly reduced. In addition, rhGH treatment significantly suppressed the S. aureus sepsis-induced elevation of TNFalpha plasma levels. CONCLUSIONS These results indicate an ability of rhGH to prevent S. aureus sepsis-induced acute lung injury in mice, which may be attributed to attenuation of increased plasma TNFalpha levels, and elevated IL-10 plasma levels as well as reduced ICAM-1 expression and inhibited NF-kappaB activity in the lungs.
Collapse
|
50
|
Wu X, Li P, Zhao J, Yang X, Wang F, Yang YQ, Fang F, Xu Y, Zhang H, Wang WY, Yi C. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type. Clin Oncol (R Coll Radiol) 2009; 20:619-25. [PMID: 18790372 DOI: 10.1016/j.clon.2008.05.011] [Citation(s) in RCA: 79] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2007] [Revised: 05/28/2008] [Accepted: 05/29/2008] [Indexed: 02/05/2023]
Abstract
AIMS To investigate the clinicopathological features, treatment outcomes, and prognostic factors in patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type. MATERIALS AND METHODS We retrospectively reviewed the medical records of 115 patients diagnosed with extranodal NK/T-cell lymphoma, nasal type who were admitted to our hospital between January 1991 and June 2006. RESULTS In total, 107 patients were available for follow-up. After the completion of treatment, 48 patients (44.9%) achieved a complete remission. By the end of the follow-up period, 60 patients (56.1%) had died from local recurrence or metastases. The mean survival duration was 70.0 months, the median survival duration was 42 months, and the 5-year survival rate was 39.4%. The mean survival durations of the three treatment groups of chemoradiotherapy, radiotherapy and palliative treatment were 91.6, 60.1 and 17.6 months, respectively. The median survival durations were 72.0, 42.0 and 10 months, respectively. Patients treated with > 50 Gy had better local control and survival than the < 50 Gy group. However, there was no significant difference between patients having fewer than four cycles of chemotherapy and patients having more than four cycles. Multifactor Cox regression model analysis showed that B symptoms, gender, International Prognostic Index (IPI) score, disease stage and therapy were all independent prognostic factors. CONCLUSIONS The prognosis of extranodal NK/T-cell lymphoma, nasal type is poor and significantly influenced by B symptoms, gender, IPI score, clinical staging and the method of treatment. Chemoradiotherapy should be the first choice for treatment.
Collapse
|